I agreed with parrot, but actually now I'm not so sure.
there is evidence of increased antiviral sales in UK this season. The way the share price increased during the swine flu outbreak was interesting. It wasn't just hot air speculation, it was based on eventual real relenza sales.
I think there is a little insider mole in the GSK sales department or maybe the pharmaceutical wholesalers. This current spike may know or care little about the current imagined management activity. i think the players have little faith in the capacity of management at BTA./ But when they get some info that suggests a little spike in sales and royalties, then they put in some play money. I think the last quater of 2010 will show almost no relenza royalties, but this current quarter could be good.
this company's management have fallen at important decision hurdles before. Relenza however tends to sell itself from time to time. Sadly, the fact relenza can still sell keeps management from making hard decisions, because their salaries are guaranteed for another year or two.
Happy to be proven wrong. I have discounted relenza to zero in my own BTA accounts. I would prefer this share spike was insider knowledge of a MA deal. If it is, that deal is set at around 1.80 - 2.00 because otherwise they would be pushing higher. Make me wonder if they think relenza royalties will earn 10-15 million this financial year.
Add to My Watchlist
What is My Watchlist?